Abstract
Objectives People living with HIV (PLWH) on antiretroviral therapy (ART) may be lost to follow-up (LTFU), which hampers the assessment of outcomes. We estimated mortality for patients starting ART in a rural region in sub-Saharan Africa and examined risk factors for death, correcting for LTFU.
Study design and setting We analysed data from Ancuabe, Mozambique, where patients LTFU are traced by phone and home visits. We used cumulative incidence functions to estimate mortality and LTFU. To correct for LTFU, we revised outcomes based on tracing data using different inverse probability weights (maximum likelihood [ML], Ridge regression or Bayesian model averaging [BMA]). We fitted competing risk models to identify risk factors for death and LTFU.
Results Analyses included 4492 patients; during 8152 person-years of follow-up, 486 patients died, 2375 were LTFU, 752 were traced, and 603 were found. At 4 years after starting ART, observed mortality was 11.9% (95% CI 10.9-13.0) but 23.5% (19.8- 28.0), 21.6% (18.7-25.0) and 23.3% (19.7- 27.6) after correction with ML, Ridge and BMA weights, respectively. Risk factors for death included male sex, lower CD4 cell counts and more advanced clinical stage.
Conclusion In ART programmes with substantial LTFU, mortality estimates need to take LTFU into account.
What is new?
Key findings
Key findings
In an antiretroviral therapy (ART) programme in Mozambique, correction of survival estimates using inverse probability weighting (IPW) of outcomes in patients lost to follow-up led to substantially higher cumulative mortality.
Correction also had an impact on some estimates of associations with risk factors for death.
What this adds to what is known?
What this adds to what is known?
This study provides new insights into the use of different IPW weights for correction of LTFU in ART programmes in sub-Saharan Africa, including maximum likelihood weights, weights from Ridge regression or Bayesian model averaging.
Results were generally similar, independently of the type of weight used. If all important covariates describing differences between patients traced and not traced are collected, an IPW approach using any of the three parameter estimation methods can be used to correct mortality for true outcomes in patients LTFU.
What is the implication and what should change now?
What is the implication and what should change now?
ART programmes with high rates of LTFU should trace patients LTFU to bring them back into care and correct programme-level estimates of mortality.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number U01AI069924. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. ME was supported by special project funding (grant 17481) from the Swiss National Science Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of the Canton of Bern (150/15) and Mozambiques National Bioethics Committee for Health (327/CNBS/15) approved the use of routine clinical data for research within the IeDEA (International epidemiology Databases to Evaluate AIDS) collaboration.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos